Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033

List of Tables

“The Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,233.6 Million by 2033.”

Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$426.3 Million
2033 Forecast	$2,233.6 Million
CAGR	18.01%

The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $426.3 million in 2023 and is expected to reach $2,233.6 million by 2033, growing at a CAGR of 18.01% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The Asia-Pacific (APAC) region is witnessing significant growth in the cell and gene therapy manufacturing quality control (QC) market. This expansion is driven by several factors, including the rising adoption of advanced therapies, increasing investments in biotechnology and pharmaceutical sectors, and the presence of a skilled workforce. Moreover, the growing prevalence of chronic diseases in the region has accelerated the demand for innovative cell and gene therapies, necessitating stringent QC measures. APAC countries are actively involved in research and development activities, fostering collaborations with biotech companies. As a result, the APAC cell and gene therapy manufacturing QC market is poised for substantial growth in the coming years, contributing to the advancement of healthcare solutions in the region.

Market Segmentation

Segmentation 1: by Therapy Type

Cell Therapy
Gene Therapy

Segmentation 2: by Offering

Products
Services

Segmentation 3: by Process

Raw Material Preparation
Upstream Processing
Downstream Processing
Packaging

Segmentation 4: by Application

Safety Testing
Potency Testing
Identity Testing
Stability and Genetic Fidelity Testing
Others

Segmentation 5: by Technology

Polymerase Chain Reaction (PCR)
Flow Cytometry
Limulus Amebocyte Lysate (LAL)
Enzyme-Linked Immunosorbent Assay (ELISA)
Chromatography
Mass Spectrometry
Western Blotting
Next-Generation Sequencing (NGS)
Electrophoresis
Other Technologies

Segmentation 6: by Country

China
Japan
South Korea
Australia
India
Rest-of-Asia-Pacific and Japan

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current APAC cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the APAC cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Product Code: BHP1817SS

Executive Summary

1. Markets

1.1. Product Definition
- 1.1.1. Product Definition
- 1.1.2. Inclusion and Exclusion Criteria
1.2. Market Scope
- 1.2.1. Key Questions Answered in the Report
1.3. Research Methodology
- 1.3.1. Cell and Gene Therapy Manufacturing QC Market
- 1.3.2. Data Sources
  - 1.3.2.1. Primary Data Sources
  - 1.3.2.2. Secondary Data Sources
- 1.3.3. Market Estimation Model
- 1.3.4. Criteria for Company Profiling
1.4. Market Overview
- 1.4.1. Market Scenario
  - 1.4.1.1. Realistic Growth Scenario
  - 1.4.1.2. Optimistic Scenario
  - 1.4.1.3. Pessimistic Scenario
- 1.4.2. Market Footprint and Growth Potential
- 1.4.3. Future Potential
- 1.4.4. COVID-19 Impact on Market
  - 1.4.4.1. Impact on Research and Clinical Operations
  - 1.4.4.2. COVID-19 Impact: Current Scenario of the Market
  - 1.4.4.3. Pre- and Post-COVID-19 Impact Assessment
    - 1.4.4.3.1. Pre-COVID-19 Phase
    - 1.4.4.3.2. Post-COVID-19 Phase

2. Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

2.1. Regulatory Framework
- 2.1.1. Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
  - 2.1.1.1. Product Testing
  - 2.1.1.2. Microbial Testing
  - 2.1.1.3. Identity
  - 2.1.1.4. Purity
  - 2.1.1.5. Potency
  - 2.1.1.6. Viability
  - 2.1.1.7. Cell Number or Dose
- 2.1.2. Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
  - 2.1.2.1. Characterization
  - 2.1.2.2. Identity Testing
  - 2.1.2.3. Purity Testing
- 2.1.3. Current Good Manufacturing Practice (CGMP) Regulations
- 2.1.4. Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3. Cell and Gene Therapy Manufacturing QC Market (by Region)

3.1. Overview
3.2. Asia-Pacific
- 3.2.2. China
  - 3.2.2.1. China Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.2.2. China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.2.3. China Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.2.4. China Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.2.5. China Cell and Gene Therapy Manufacturing QC Market (by Application)
- 3.2.3. Japan
  - 3.2.3.1. Japan Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.3.2. Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.3.3. Japan Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.3.4. Japan Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.3.5. Japan Cell and Gene Therapy Manufacturing QC Market (by Application)
- 3.2.4. South Korea
  - 3.2.4.1. South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.4.2. South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.4.3. South Korea Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.4.4. South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.4.5. South Korea Cell and Gene Therapy Manufacturing QC Market (by Application)
- 3.2.5. Australia
  - 3.2.5.1. Australia Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.5.2. Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.5.3. Australia Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.5.4. Australia Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.5.5. Australia Cell and Gene Therapy Manufacturing QC Market (by Application)
- 3.2.6. India
  - 3.2.6.1. India Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.6.2. India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.6.3. India Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.6.4. India Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.6.5. India Cell and Gene Therapy Manufacturing QC Market (by Application)
- 3.2.7. Rest-of-Asia-Pacific
  - 3.2.7.1. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
  - 3.2.7.2. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  - 3.2.7.3. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
  - 3.2.7.4. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
  - 3.2.7.5. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

4. Company Profiles

4.1. Overview
4.2. Manufacturers
- 4.2.1. WuXi AppTec
  - 4.2.1.1. Company Overview
  - 4.2.1.2. Role of WuXi AppTec in the Cell and Gene Therapy Manufacturing QC Market
  - 4.2.1.3. Key Competitors
  - 4.2.1.4. Financials
  - 4.2.1.5. Analyst Perspective

Product Code: BHP1817SS

List of Figures

Figure 1: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
Figure 2: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
Figure 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
Figure 4: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
Figure 5: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
Figure 6: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
Figure 7: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
Figure 14: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
Figure 15: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
Figure 16: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
Figure 17: Impact of COVID-19 on CGT Developmental Activities
Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
Figure 19: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 20: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
Figure 21: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 22: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 23: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 24: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 25: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 26: China Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 27: China Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 28: China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 29: China Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 30: China Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 31: China Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 32: Japan Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 33: Japan Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 34: Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 35: Japan Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 36: Japan Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 37: Japan Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 38: South Korea Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 39: South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 40: South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 41: South Korea Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 42: South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 43: South Korea Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 44: Australia Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 45: Australia Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 46: Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 47: Australia Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 48: Australia Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 49: Australia Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 50: India Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 51: India Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 52: India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 53: India Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 54: India Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 55: India Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 56: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
Figure 57: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
Figure 58: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
Figure 59: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
Figure 60: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
Figure 61: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
Figure 62: Total Number of Companies Profiled
Figure 63: WuXi AppTec: Product Portfolio
Figure 64: WuXi AppTec: Overall Financials, $Million, 2020-2022
Figure 65: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

Table 1: Key Questions Answered in the Report
Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
Table 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis
Table 4: Approved Cell and Gene Therapies, Japan

Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033

Description

Table of Contents

List of Tables

Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

Market Introduction

Market Segmentation

Segmentation 1: by Therapy Type

Segmentation 2: by Offering

Segmentation 3: by Process

Segmentation 4: by Application

Segmentation 5: by Technology

Segmentation 6: by Country

How can this report add value to an organization?

Table of Contents

Executive Summary

1. Markets

2. Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

3. Cell and Gene Therapy Manufacturing QC Market (by Region)

4. Company Profiles

List of Figures

List of Tables